Sign up to save your podcasts
Or
Share Prof. Michael Hofman
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Prof. Michael Hofman
Professor Michael Hofman discusses the phase II results of the TheraP trial and what these results mean for patient's with castration-resistant prostate cancer.
View all episodes
By Ariez PublishingProfessor Michael Hofman discusses the phase II results of the TheraP trial and what these results mean for patient's with castration-resistant prostate cancer.